Back

Sagimet closes $115 million offering to fund denifanstat trials

Verifying
  • Sagimet closed an underwritten offering of Series A shares and pre-funded warrants.
  • The offering generated approximately $115.0 million in gross proceeds before expenses.
  • Sagimet plans to fund denifanstat, TVB-3567 and topical FASN inhibitor development.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.